title: [Can mepartricin be considered an antiandrogenic drug?].
authors.affiliation: Istituto di Clinica Urologica, Università degli Studi di Chieti.
authors.forename: C
authors.initials: C
authors.lastname: Lubrano
authors.forename: P
authors.initials: P
authors.lastname: Bianchi
authors.forename: T
authors.initials: T
authors.lastname: Verna
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D000726:Androgen Antagonists / Q000378:metabolism / Q000494:pharmacology / Q000627:therapeutic use*; D001667:Binding, Competitive; D002467:Cell Nucleus / Q000378:metabolism; D003600:Cytosol / Q000378:metabolism; D006801:Humans; D008297:Male; D008613:Mepartricin / Q000378:metabolism / Q000494:pharmacology / Q000627:therapeutic use*; D015741:Metribolone / Q000378:metabolism; D008875:Middle Aged; D011467:Prostate / Q000187:drug effects* / Q000378:metabolism; D011468:Prostatectomy; D011470:Prostatic Hyperplasia / Q000188:drug therapy* / Q000601:surgery; D011944:Receptors, Androgen / Q000187:drug effects / Q000378:metabolism*
chemical_list: D000726:Androgen Antagonists; D011944:Receptors, Androgen; D008613:Mepartricin; D015741:Metribolone